ADC Therapeutics to Present at the Jefferies Healthcare Conference

LAUSANNE, Switzerland--(BUSINESS WIRE)-- ADC Therapeutics SA (NYSE: ADCT) announced today that its Chief Executive Officer, Ameet Mallik, will be participating in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 9:00 am ET.

A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics’ website, ir.adctherapeutics.com. A replay of the webcast will be available for approximately 30 days.

About ADC Therapeutics

ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

ADC Therapeutics’ CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large b-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents. Cami (camidanlumab tesirine) is being evaluated in a pivotal Phase 2 trial for relapsed or refractory Hodgkin lymphoma and in a Phase 1b clinical trial for various advanced solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.

ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the Company on Twitter and LinkedIn.

ZYNLONTA® is a registered trademark of ADC Therapeutics SA.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220601005177/en/

Investors

Eugenia Litz
ADC Therapeutics
[email protected]
+44 7879 627205

Amanda Hamilton
ADC Therapeutics
[email protected]
+1 917-288-7023

Media

Mary Ann Ondish
ADC Therapeutics
[email protected]
+1 914-552-4625

Source: ADC Therapeutics SA

You May Also Be Interested In

• Chemtrade Logistics Income Fund Announces Results for the Second Quarter of 2026 and Reiterates 2026 Adjusted EBITDA Guidance of $485 to $525 Million
• Southland Announces Second Quarter 2026 Results
• Sherritt Reports Second Quarter 2026 Results